CARL CARLSMED, INC.
FY2025 10-K
CARLSMED, INC. (CARL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: proprietary aprevo platform for personalized spine fusion surgical implants using AI-driven surgical planning software
- • New: 2025 launch of FDA-cleared aprevo cervical spine fusion technology and personalized cervical plating solutions
Management Discussion & Analysis
- • No revenue, segment, or profitability details disclosed in this MD&A excerpt
- • Risks highlighted on liquidity due to loan covenants and uninsured cash deposits exposure
Financial SummaryXBRL
Revenue
$51M
Net Income
-$30M
Gross Margin
75.3%
Operating Margin
-60.5%
Net Margin
-58.7%
ROE
-30.0%
Total Assets
$130M
EPS (Diluted)
$-2.12
Operating Cash Flow
-$29M
Source: XBRL data from CARLSMED, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CARLSMED, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.